Modulators of the nmda receptor

A compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:

• R1 is selected from the group consisting of a hydrogen, halogen, C1-4 haloalkyl, cyano, C3-6 cycloalkyl, and C1-4 alkyl;
• R2 is selected from the group consisting of hydrogen, halogen, C1-4 haloalkyl, cyano, C3-6 cycloalkyl, and C1-4 alkyl;
• R3 is selected from the group consisting of hydrogen, halogen, C1-4 haloalkyl, cyano, C3-6 cycloalkyl, and C1-4 alkyl;
• R4 is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 hydroxyhaloalkyl, cyano, NRaRb, SRcRd, OR6, L-(OR6), and R7;
• Ra and Rb are independently selected from the group consisting of hydrogen and C1-4 alkyl;
• Rc and Rd are independently selected from the group consisting of hydrogen and C1-4 alkyl;
• R6 is selected from the group consisting of hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, and C1-4 hydroxyhaloalkyl;
• L represents a C1-3 alkylene;
• and
• R7 is selected from the group consisting of C3-6 cycloalkyl, phenyl, 4, 5, or 6 membered heterocycle, and 5 or 6 membered heteroaryl, wherein said cycloalkyl, phenyl, heterocycle or heteroaryl are independently unsubstituted or substituted with 1, 2 or 3 substituents independently selected from halogen, C1-3 alkyl, C1-3 alkoxy, wherein said C1-3 alkyl and C1-3 alkoxy are independently unsubstituted or substituted with 1, 2 or 3 F.